**Highlights of This Issue**  4303

**SPECIAL FEATURES**

**Editorial**

4305  Food and Oral Antineoplastics: More Than Meets the Eye  
Rajul K. Jain, Satjit S. Brar, and Lawrence J. Lesko  
See article p. 4446

**CCR Translations**

4308  Personalized Tamoxifen: A Step Closer but Miles To Go  
Aditya Bardia and Vered Stearns  
See article p. 4468

4311  Arsenic Trioxide and the Phosphoinositide 3-Kinase/Akt Pathway in Chronic Lymphocytic Leukemia  
Dennis J. Goussetis and Leonidas C. Platanias  
See article p. 4382

**CCR New Strategies**

4313  New Strategies in Pancreatic Cancer: Emerging Epidemiologic and Therapeutic Concepts  
Donghui Li and James L. Abbruzzese

**Molecular Pathways**

4319  Overcoming Persistent Dependency on Androgen Signaling after Progression to Castration-Resistant Prostate Cancer  
Masuo Yamaoka, Takahito Har, and Masami Kusaka

4325  PI(3)King Apart PTEN's Role in Cancer  
Siyuan Zhang and Dihua Yu

**Report from the FDA**

4331  U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab  
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilato, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan, and Richard Pazdur

**HUMAN CANCER BIOLOGY**

4339  Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F  

4353  Meta-analysis of Neuroblastomas Reveals a Skewed ALK Mutation Spectrum in Tumors with MYCN Amplification  
Sara De Brouwer, Katleen De Preter, Candy Kumps, Piotr Zabrocki, Michael Porcu, Ellen M. Westerhout, Arjan Lakeman, Jo Vandesompele, Jasmin Hoebeck, Tom Van Marcken, Anne De Paepe, Genevieve Laureys, Johannes H. Schulte, Alexander Schramm, Caroline Van Den Broecke, Joëlle Vermeulen, Nadine Van Roy, Klaus Beiske, Marleen Renard, Rosa Noguera, Olivier Delattre, Isabelle Janoueix-Lerosey, Per Kogner, Tommy Martinsson, Akira Nakagawara, Miki Ohira, Huib Caron, Angelika Eggert, Jan Cools, Rogier Versteeg, and Frank Speleman

4363  Upregulation of SOX9 in Lung Adenocarcinoma and Its Involvement in the Regulation of Cell Growth and Tumorogenicity  
Shih Sheng Jiang, Wen-Tsuen Fang, Ya-Hsue Hou, Shi-Feng Huang, B. Linju Yen, Jun-Liang Chang, Shih-Miao Li, Hui-Ping Liu, Ying-Lan Liu, Chih-Ting Huang, Yu-Wei Li, Te-Hsuan Iang, Shih-Hsuan Chan, Su Jing Yang, Chao A. Hsiung, Cheng-Wen Wu, Lu-Hai Wang, and I-Shou Chang

---

The Journal of Clinical and Translational Research

September 1, 2010 • Volume 16 • Number 17
The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group

Prediction of Stage, Grade, and Survival in Bladder Cancer Using Genome-wide Expression Data: A Validation Study
Martin Lauss, Markus Ringnér, and Mattias Höglund

Induction of B-Chronic Lymphocytic Leukemia Cell Apoptosis by Arsenic Trioxide Involves Suppression of the Phosphoinositide 3-Kinase/Akt Survival Pathway via c-jun-NH₂ Terminal Kinase Activation and PTEN Upregulation
Javier Redondo-Muñoz, Elizabeth Escobar-Díaz, Mercedes Hernández del Cerro, Atanasio Pandiella, María José Terol, José A. García-Marco, and Angeles García-Pardo
See commentary p. 4311

Actinomycin D Decreases Mcl-1 Expression and Acts Synergistically with ABT-737 against Small Cell Lung Cancer Cell Lines
Haishan Xu and Geoffrey W. Krystal

Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung Cancer
Marco Alifano, Frédérique Souazé, Sandra Dupouy, Sophie Camilleri-Broët, Mohamad Younes, Sadi-Menad Ahmed-Zaïd, Takashi Takahashi, Alessandra Cancellieri, Stefania Damiani, Maurizio Boaron, Philippe Broët, Lance D. Miller, Christian Gespach, Jean François Regnard, and Patricia Forgez

Notch1 Expression Predicts an Unfavorable Prognosis and Serves as a Therapeutic Target of Patients with Neuroblastoma
Hsiu-Hao Chang, Hsinyu Lee, Ming-Kuan Hu, Po-Nien Tsao, Hsueh-Fen Juan, Min-Chuan Huang, Yu-Yin Shih, Bo-Jeng Wang, Yung-Ming Jeng, Christina Ling Chang, Shiu-Feng Huang, Yeou-Guang Tsay, Fon-Jou Hsieh, Kai-Hsin Lin, Wen-Ming Hsu, and Yung-Feng Liao

Preclinical and Clinical Evidence that Deoxy-2-[¹⁸F]fluoro-D-glucose Positron Emission Tomography with Computed Tomography Is a Reliable Tool for the Detection of Early Molecular Responses to Erlotinib in Head and Neck Cancer
Sébastien Vergez, Jean-Pierre Delord, Fabienne Thomas, Philippe Rochaix, Olivier Caselles, Thomas Filleron, Séverine Brillouet, Pierre Canal, Frédéric Courbon, and Ben C. Allal

Inconsistent Labeling of Food Effect for Oral Agents across Therapeutic Areas: Differences between Oncology and Non-Oncology Products
Soonmo Peter Kang and Mark J. Ratain
See commentary p. 4305

Histopathologic and Immunohistochemical Characterization of Rash to Human Epidermal Growth Factor Receptor 1 (HER1) and HER1/2 Inhibitors in Cancer Patients
Beatrice Nardone, Kimberly Nicholson, Marissa Newman, Joan Guitart, Pedram Gerami, Nicholas Talarico, Ximing J. Yang, Alfred Rademaker, Dennis P. West, and Mario E. Lacouture
The Effectiveness of Off-Protocol Adjuvant Chemotherapy for Patients with Urothelial Carcinoma of the Urinary Bladder


CYP2D6 Polymorphisms as Predictors of Outcome in Breast Cancer Patients Treated with Tamoxifen: Expanded Polymorphism Coverage Improves Risk Stratification

Werner Schroth, Ute Hamann, Peter A. Fasching, Silke Dauser, Stefan Winter, Michel Eichelbaum, Matthias Schwab, and Hiltrud Brauch

See commentary p. 4308

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli

Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants

4490

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli

Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants

4490

Preclinical and Clinical Estimates of the Basal Apoptotic Rate of a Cancer Predict the Amount of Apoptosis Induced by Subsequent Proapoptotic Stimuli

Lian Zhang, Brian D. Kavanagh, Andrew M. Thorburn, and D. Ross Camidge

Correction: Biobehavioral, Immune, and Health Benefits following Recurrence for Psychological Intervention Participants

4490

This is an original study providing, from preclinical models to patients, a reliable proof of \(^{18}\text{FDG-PET}/\text{CT}\) efficiency as a surrogate marker for the early evaluation of \(\text{EGFR-TKI}\) (erlotinib) efficacy that may improve diagnostic accuracy of molecular effect (ERK1/2). The image represents a facial sagittal section of an \(^{18}\text{FDG-PET}/\text{CT}\) of a patient with an oropharyngeal head and neck squamous cell carcinoma. It reveals a tumor \(^{18}\text{FDG}\) uptake before patient exposure to erlotinib. For further details, please see the article by Vergez and colleagues on page 4434 of this issue.